Logo image of LIXT

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock Fundamental Analysis

USA - NASDAQ:LIXT - US5393193017 - Common Stock

4.75 USD
+0.34 (+7.71%)
Last: 11/12/2025, 8:00:02 PM
4.75 USD
0 (0%)
After Hours: 11/12/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, LIXT scores 1 out of 10 in our fundamental rating. LIXT was compared to 531 industry peers in the Biotechnology industry. LIXT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LIXT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LIXT has reported negative net income.
LIXT had a negative operating cash flow in the past year.
LIXT had negative earnings in each of the past 5 years.
LIXT had a negative operating cash flow in each of the past 5 years.
LIXT Yearly Net Income VS EBIT VS OCF VS FCFLIXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

LIXT has a worse Return On Assets (-259.89%) than 92.84% of its industry peers.
LIXT's Return On Equity of -474.14% is on the low side compared to the rest of the industry. LIXT is outperformed by 76.27% of its industry peers.
Industry RankSector Rank
ROA -259.89%
ROE -474.14%
ROIC N/A
ROA(3y)-181.53%
ROA(5y)-147.83%
ROE(3y)-227.63%
ROE(5y)-177.69%
ROIC(3y)N/A
ROIC(5y)N/A
LIXT Yearly ROA, ROE, ROICLIXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LIXT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIXT Yearly Profit, Operating, Gross MarginsLIXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for LIXT remains at a similar level compared to 1 year ago.
LIXT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LIXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LIXT Yearly Shares OutstandingLIXT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
LIXT Yearly Total Debt VS Total AssetsLIXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -48.70, we must say that LIXT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -48.70, LIXT is doing worse than 93.41% of the companies in the same industry.
LIXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -48.7
ROIC/WACCN/A
WACCN/A
LIXT Yearly LT Debt VS Equity VS FCFLIXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

2.3 Liquidity

LIXT has a Current Ratio of 1.84. This is a normal value and indicates that LIXT is financially healthy and should not expect problems in meeting its short term obligations.
LIXT has a Current ratio of 1.84. This is in the lower half of the industry: LIXT underperforms 78.72% of its industry peers.
LIXT has a Quick Ratio of 1.84. This is a normal value and indicates that LIXT is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of LIXT (1.84) is worse than 76.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
LIXT Yearly Current Assets VS Current LiabilitesLIXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.79% over the past year.
EPS 1Y (TTM)29.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LIXT Yearly Revenue VS EstimatesLIXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 50K 100K 150K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LIXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIXT Price Earnings VS Forward Price EarningsLIXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIXT Per share dataLIXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LIXT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIXTE BIOTECHNOLOGY HOLDINGS

NASDAQ:LIXT (11/12/2025, 8:00:02 PM)

After market: 4.75 0 (0%)

4.75

+0.34 (+7.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-23 2026-03-23
Inst Owners6.34%
Inst Owner Change29.65%
Ins Owners4.21%
Ins Owner Change0%
Market Cap21.66M
Revenue(TTM)N/A
Net Income(TTM)-3.09M
Analysts0
Price TargetN/A
Short Float %1.8%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 33.25
P/tB 33.25
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -259.89%
ROE -474.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-181.53%
ROA(5y)-147.83%
ROE(3y)-227.63%
ROE(5y)-177.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -48.7
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.92%
OCF growth 3YN/A
OCF growth 5YN/A

LIXTE BIOTECHNOLOGY HOLDINGS / LIXT FAQ

Can you provide the ChartMill fundamental rating for LIXTE BIOTECHNOLOGY HOLDINGS?

ChartMill assigns a fundamental rating of 1 / 10 to LIXT.


What is the valuation status for LIXT stock?

ChartMill assigns a valuation rating of 0 / 10 to LIXTE BIOTECHNOLOGY HOLDINGS (LIXT). This can be considered as Overvalued.


What is the profitability of LIXT stock?

LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) has a profitability rating of 0 / 10.


How financially healthy is LIXTE BIOTECHNOLOGY HOLDINGS?

The financial health rating of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) is 5 / 10.


How sustainable is the dividend of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) stock?

The dividend rating of LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) is 0 / 10 and the dividend payout ratio is 0%.